sr-1

StemRegenin 1 (SR1) is an aryl hydrocarbon receptor (AhR) inhibitor.

Anti-c-Kit/CD117 Antibody (SR-1) is a mouse IgG2a, κ chimeric antibody that specifically targets human c-Kit/CD117. The recommended isotype control for this antibody is Mouse IgG2a kappa, Isotype Control.

SR-1277 is a potent, highly selective and ATP-competitive CK1δ/ε inhibitor with IC50 values of 49 nM and 260 nM, respectively.CK1δ plays a crucial role in regulating Wee1 activity at the G2/M cell-cycle interface, and exhibits significant antiproliferative activity against a variety of cancer cells.

SR-12062 functions as a full agonist at neurotensin receptor 1 (NTSR1), demonstrating notable efficacy and increased potency. Its EC50 value on NTSR1 is 2 μM, with complete receptor activation (Emax=100%). Compared to the parent compound 1 (EC50=178 μM; Emax=17%), SR-12062 shows approximately 90-fold greater potency.

SR-17398 is an inhibitor of Unc-51-Like Kinase 1 (ULK1) (IC50 = 22.4 uM).

SR-1114, a first-in-class PROTAC ENL degrader, induces rapid CRBN-dependent ENL degradation with DC50 values of 150 nM in MV4;11 cells, 311 nM in MOLM-13 cells, and 1.65 μM in OCI/AML-2 cells [1].

ESR-1150 HCl is an agonist of the alpha(1L)-adrenoceptor.

GHSR-1a agonist-1 (Compound 4b) is an orally active agonist of the human growth hormone secretagogue receptor 1a (GHSR-1a) with an EC50 of 0.49 nM. It effectively stimulates the release of endogenous growth hormone by activating GHSR-1a. Doses as low as 0.1 mg/kg (administered orally) can increase body weight and length in 4-week-old rats. GHSR-1a agonist-1 is applicable in research on pediatric growth and developmental delays.

SR-140603, the less potent enantiomer of SR 140333, is used as the negative control.

SSR-182289A (Free) is a thrombin inhibitor.

DSR-141562 is a new compound that can be taken orally and has a specific ability to inhibit phosphodiesterase 1 (PDE1) in the brain. This compound exhibits a preference for inhibiting human PDE1B, with an IC50 value of 43.9 nM. It also shows moderate inhibition of human PDE1A (IC50 = 97.6 nM) and PDE1C (IC50 = 431.8 nM). DSR-141562 is particularly useful in the study of positive symptoms, negative symptoms, and cognitive impairments associated with schizophrenia.

SR-18292 is an inhibitor of PPAR gamma coactivator-1α (PGC-1α), which increases PGC-1α acetylation, suppresses gluconeogenic gene expression and reduces glucose production in hepatocytes.

HSR-175 HCl is an alpha 1-adrenoceptor antagonist.

Meclinertant (SR 48692) is a neurotensin receptor-1 (NT1) antagonist that blocks neurotensin-induced excitation and can be used to study neurological disorders.

Rimonabant hydrochloride (SR 141716A) is a cannabinoid receptor antagonist, binding selectively to central cannabinoid receptors (CB1) with high affinity.

Irbesartan (SR-47436) is an Angiotensin 2 Receptor Blocker whose mechanism of action involves antagonizing the Angiotensin 2 Receptor.

ML-180 (SR1848) is a potent inverse agonist of the orphan nuclear receptor liver receptor homolog 1 (LRH-1; NR5A2) with an IC50 of 3.7 μM.

BLT-1 is a scavenger receptor BI (SR-BI)inhibitor.

Mifobate (SR-202) is a potent and specific antagonist of PPARγ, exhibiting antiobesity, antidiabetic, and antiatherosclerotic effects[1].

SR 146131 is a potent and selective agonist of the nonpeptide receptor.

SR 142948-C3-NHMe is the methylated form of SR 142948.

MASTL/Aurora A-IN-1 (Compound MA4) is a dual inhibitor of MASTL and Aurora A kinases, with IC50 values of 0.56 μM and 0.16 μM, respectively. This compound exhibits broad-spectrum anticancer activity, demonstrating potent effects against NCI-60 cancer cell lines, including SR (leukemia), K-562 (leukemia), MDA-MB-435 (melanoma), MOLT-4 (leukemia), and SK-MEL-2 (melanoma) with GI50 values of 0.023, 0.032, 0.037, 0.044, and 0.051 μM. By inhibiting Aurora A and MASTL kinases, MASTL/Aurora A-IN-1 induces G2/M phase cell cycle arrest, thereby impeding cancer cell proliferation. This compound is applicable for cancer research, particularly in the study of tumors with mitotic dysregulation.

RyR2 stabilizer-1 (Compound12a) is a potent stabilizer of RyR2 and an activator of SERCA2a, with EC50 values of 2.7 μM for RyR2 and 383 nM for SERCA2. This compound inhibits the leakage of Ca2+ through SR RyR2 while promoting the reuptake of Ca2+ into the SR by SERCA2, suggesting its potential in preventing arrhythmias.

SR 11302 is an inhibitor of activator protein-1 (AP-1).